Hepatitis C virus-polymerase chain reaction minipool testing: 3 years in the largest Swiss blood transfusion service

Vox Sanguinis

Volumn 84, Issue 2, 2003, Pages 105-110

  Stolz, M ^a   Gilgen, M ^a   Niederhauser, C ^a,b  

^a Blood Transfusion Service SRC Berne   (Switzerland)

^b Swissmedic   (Switzerland)

Author keywords

BioRobot; COBAS Amplicor; HCV PCR; Hepatitis C virus; Minipool testing; Preseroconversion window period

Indexed keywords

EDETIC ACID; HEPATITIS C ANTIBODY; VIRUS RNA;

ANTIBODY DETECTION; ARTICLE; BLOOD; BLOOD SAMPLING; BLOOD TRANSFUSION; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAFETY; SEROCONVERSION; SWITZERLAND; VIRUS LOAD;

BLOOD PRESERVATION; BLOOD TRANSFUSION; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; POLYMERASE CHAIN REACTION; SAFETY; SENSITIVITY AND SPECIFICITY; SWITZERLAND;

EID: 0037989841     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00263.x     Document Type: Article

References (16)

1. Choo Q-L,Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-bome non-A, non-B viral hepatitis genome. Science 1989;244:359-362
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-1690
3. Burckhardt JJ: Assessment of needs for plasma for fractionation in Europe. Biologicals 1999;27:337-341
4. Schweizerische Eidgenossenschaft: Verordnung über die Kontrolle von Blut, Blutprodukten und Transplantaten. SR 818.111.3. Berne, Switzerland, 1996
5. European Agency for the Evaluation of Medicinal Products: Validation of Analytical Methods: Methodology. CPMP/ICH/291/95. London, UK, 2001
6. PEI: Anforderungen an Validierung bzw. Routinebetrieb der HCV-NAT im Blutspendewesen. Langen, Germany, 1999 [http://www.pei.de/massnahm/valid.htm]
7. Bundesamt für Gesundheit: NAT an Blutspenden: Technische Richtlinien. Berne, Switzerland, 1999 [http://www.bag.admin.ch/heilmitt/biologik/gesetze/d/nat_rlin.htm]
8. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999; 353:359-363
9. Seifried E, Roth WK: Prospective survey of HCV, HBV, HIV-1 NAT screening of more than 10 million blood donors in the Red Cross blood service centers in Germany. Transfus Clin Biol 2001; 8:17s
10. Reesink HW, Cuypers HTM, Sjerps MC, Hopman H, Jongerius JM, Molijn MH, Peeters GAH, Peeters APW, Nelis H, Mollet FE, Van Der Poel CL, Lelie PN: Minipool screening for HCV-RNA and HIV-RNA by automated extraction, amplification and detection. Transfus Clin Biol 2001; 8:17s-18s
11. Love EM, Tedder RS, Sims CM, Bedford R: The science and methodology of NAT HCV implementation in the National Blood Service (NBS), England. Transfus Clin Biol 2001; 8:33s-34s
12. Japanese Red Cross NAT Screening Research Group: Nationwide NAT screening of HBV, HCV and HIV-1 for blood transfusion in Japan. Transfus Clin Biol 2001; 8:56s-57s
13. Brojer E, Nuznik A, Liszewski G, Krug-Janiak M, Rosiek A, Medynska J, Sablinski J, Letowska M: HCV-NAT screening of mini-pools in Poland. Transfus Clin Biol 2001; 8:88s
14. Grob PJ, Negro F, Renner EL: Hepatitis C virus infektion. Praxis 2000; 89:1587-1604
15. Roth WK, Buhr S, Drosten C, Seifried E: NAT and viral safety in blood transfusion. Vox Sang 2000; 78:257-259
16. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S: Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000; 40:143-159